22157.jpg
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
November 05, 2021 05:58 ET | Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention Research
August 24, 2021 10:30 ET | Cancer Advances Inc
DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in...
logo.jpg
Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
August 04, 2021 08:30 ET | Processa Pharmaceuticals, Inc.
Processa’s Phase 1b open label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for...
New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
April 28, 2021 12:35 ET | Provectus Biopharmaceuticals Inc.
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) — Systemic administration of PV-10 for treatment of solid tumor...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Abstract at AACR
March 23, 2021 08:00 ET | Cancer Advances Inc
DURHAM, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that an abstract...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Poster Presentation at ASCO GI
January 21, 2020 22:20 ET | Cancer Advances Inc
DURHAM, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will present a poster at the...
Cancer Advances, Inc. announces a new publication “Vaccine Against Gastrin, a Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases” in the American Journal of Physiology—Gastrointestinal and Liver Physiology
November 11, 2019 03:00 ET | Cancer Advances Inc
Immune competent female mice with pancreatic cancer treated with Polyclonal Antibody Stimulator (PAS) vaccine had significantly smaller tumors and fewer metastases than control mice. PAS vaccine...
Cancer Advances, Inc. announces new publication: “Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment”, in the journal Cancer Immunology, Immunotherapy
November 11, 2019 02:00 ET | Cancer Advances Inc
Inactivation of the growth peptide gastrin modulates the tumor microenvironment of pancreatic cancer rendering it more susceptible to immune checkpoint antibody therapy.Polyclonal Antibody Stimulator...
gmi 2018.png
Carcinoembryonic Antigen Market will expand at 6.7% CAGR to hit $3 bn by 2024: Global Market Insights, Inc.
January 15, 2019 05:00 ET | Global Market Insights, Inc
Sellbyville, Delaware, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Japan dominated the Asian carcinoembryonic antigen market and was valued around USD 74.6 million in the year 2017. Growing awareness about...
Rafael_Pharma-Logo+Slogan.png
Rafael Pharmaceuticals Appoints Two Prominent Gastrointestinal Oncologists from Europe to its Medical Advisory Board to Support Global Development of CPI-613 in Pancreatic Cancer and Other Gastrointestinal Malignancies
July 13, 2018 09:15 ET | Rafael Pharmaceutical Inc.
Newark, NJ, July 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Eric Van Cutsem...